Evotec Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Christian Wojczewski

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Christian Wojczewski (52 yo)

less than a year

Görev süresi

Dr. Christian Wojczewski serves as Chief Executive Officer of Evotec SE since July 01, 2024. He holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe University in Frankfurt am Main....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Laetitia Rouxel	CFO & Member of Management Board	1.7yrs	€890.00k	0.029% € 434.4k
Cord Dohrmann	Chief Scientific Officer & Member of Management Board	14.3yrs	€1.48m	0.11% € 1.6m
Craig Johnstone	COO & Member of Management Board	5.9yrs	€1.18m	0.011% € 169.5k
Christian Wojczewski	Chief Executive Officer	less than a year	Veri yok	Veri yok
Aurelie Dalbiez	Chief People Officer & Member of Management Board	less than a year	Veri yok	Veri yok
Volker Braun	Executive VP and Head of Global Investor Relations & ESG	no data	Veri yok	Veri yok
Christian Dargel	EVP Global Head of Legal & Compliance	no data	Veri yok	Veri yok
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	no data	Veri yok	Veri yok
Ian Hunneyball	Senior Vice President of Programme Management & Clinical Operations	no data	€116.00k	Veri yok
David Hallet	Executive Vice President	no data	Veri yok	Veri yok
Uwe Andag	EVP Head of Metabolic Diseases	no data	Veri yok	Veri yok
Christiane Honisch	SVP Head of Diagnostics	no data	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 0IRF 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Roland Sackers	Independent Vice Chairperson of the Supervisory Board	5.5yrs	€95.00k	Veri yok
Iris Loew-Friedrich	Independent Chairperson of the Supervisory Board	10.5yrs	€150.00k	Veri yok
Duncan McHale	Member of the Supervisory Board	less than a year	Veri yok	Veri yok
Camilla Languille	Member of the Supervisory Board	2.5yrs	€60.00k	Veri yok
Constanze Ulmer-Eilfort	Independent Member of Supervisory Board	3.5yrs	€85.00k	Veri yok
Wesley Wheeler	Independent Supervisory Board	less than a year	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0IRF 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/27 19:52
Gün Sonu Hisse Fiyatı	2024/12/27 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Evotec SE 35 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Volker Bosse	Baader Helvea Equity Research
Laura Lopez Pineda	Baader Helvea Equity Research
Gerhard Schwarz	Baader Helvea Equity Research

Evotec Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Evotec SE Announces Craig Johnstone to Step Down and Leave as Chief Operating Officer, Effective 31 December 2024

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE, Annual General Meeting, Jun 20, 2023

Recent updates

Evotec SE Announces First Projects for LAB eN2 Drug Discovery Accelerator with Novo Nordisk

Evotec SE Announces Craig Johnstone to Step Down and Leave as Chief Operating Officer, Effective 31 December 2024

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Second quarter 2024 earnings released: €0.54 loss per share (vs €0.084 loss in 2Q 2023)

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings released: €0.47 loss per share (vs €0.99 loss in FY 2022)

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings released: €0.22 loss per share (vs €0.27 loss in 3Q 2022)

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €0.99 loss per share (vs €1.30 profit in FY 2021)

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Third quarter 2022 earnings released: €0.27 loss per share (vs €0.82 profit in 3Q 2021)

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Second quarter 2022 earnings released: €0.16 loss per share (vs €0.36 profit in 2Q 2021)

Evotec SE Revises Revenue Guidance for the Full Year 2022

Investor sentiment improved over the past week

Now 20% undervalued

Now 23% undervalued after recent price drop

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 21% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Evotec SE Confirms Revenue Guidance for 2022

Full year 2021 earnings released: EPS: €1.30 (vs €0.041 in FY 2020)

Full year 2021 earnings released: EPS: €1.30 (vs €0.041 in FY 2020)

Evotec Se Provides Revenue Guidance for 2022

Now 25% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Third quarter 2021 earnings released: EPS €0.82 (vs €0.009 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.36 (vs €0.065 loss in 2Q 2020)

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Independent Chairman of Supervisory Board Wolfgang Plischke has left the company

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

First quarter 2021 earnings released: EPS €0.32 (vs €0.11 in 1Q 2020)

Evotec SE Launches 'beLAB1407' to Accelerate Translational Research from the UK's Academic Life Science Ecosystem in Collaboration with Bristol Myers Squibb

Full year 2020 earnings released: EPS €0.041 (vs €0.25 in FY 2019)

Evotec SE Provides Earnings Guidance for the Year 2021

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş